FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387362004> ?p ?o ?g. }

• W4387362004 abstract "Abstract Disclosure: F. Costanza: None. S. Chiloiro: None. A. Giampietro: None. P. Mattogno: None. A. Infante: None. F. Angelini: None. L. Lauretti: None. A. Olivi: None. A. Pontecorvi: None. F. Doglietto: None. L. De Marinis: None. A. Bianchi: None. Acromegaly is associated with skeletal fragility and an increased prevalence of vertebral fractures (VF). In recent years several authors have tried to investigate the markers that can predict the risk of bone fragility in this endocrine disorder. Two different isoforms of the GH receptor (GHR) have been described so far, which differ in the presence or absence of a transcript of exon 3 of the GHR gene. Both isoforms produce a functional receptor, but the exon 3-deleted isoforms (d3-GHR) have greater sensitivity to endogenous and recombinant GH than the full-length isoform (fl-GHR). We conducted a longitudinal, retrospective, observational, single-center study of first-generation SSA-resistant acromegaly patients, with the aim of investigating the role of GHR polymorphism as a prognostic factor of incidental VF (I-VF) in first-generation SSA-resistant acromegalic patients and treated with GH receptor antagonist (Pegvisomant) or second-generation somatostatin ligand (Pasireotide Lar).72 patients with acromegaly were included. 28 patients carried d3-GHR isoform (38.9%) and 44 patients carried fl-GHR isoform (61.1%). At baseline, all patients were affected by active acromegaly; 46 patients were treated with Pegvisomant in combination with first generation SSA and 26 were treated with Pasireotide Lar. 18 patients (25%) carried P-VFs. At last follow-up, 58 patients achieved biochemical control of acromegaly (80.6%). 14 patients experienced the occurrence of I-VFs. From the group treated with Pegvisomant in combination with first generation SSA, 32 patients carried fl-GHR polymorphism and 14 carried d3-GHR polymorphism. At baseline, 10 patients (21.7%) were I-VF carriers. At follow-up, 8 patients developed P-VF (17.4%). I-VF occurred more frequently in patients carrying fl-GHR isoform compared to d3-GHR (p=0.04). From the group treated with Pasireotide Lar, 12 patients carried fl-GHR isoform and 14 patients carried d3-GHR isoform. At baseline, 8 patients (30.8%) were I-VF carriers. At follow-up, 6 patients developed P-VF (23.1%). I-VF occurred more frequently in patients carrying d3-GHR isoform than fl-GHR (p=0.01) and in patients with P-VF as compared to patients without P-VF (p=0.05).In conclusion, the GH receptor polymorphism could assume greater relevance as a prognostic factor of VF in acromegaly patients. In the future, the knowledge of the GHR polymorphism may improve the therapeutic approach of acromegaly patients, tailored to the individual patient, in the context of personalized medicine. Presentation: Thursday, June 15, 2023" @default.
• W4387362004 created "2023-10-06" @default.
• W4387362004 creator A5011213787 @default.
• W4387362004 creator A5028154666 @default.
• W4387362004 creator A5029381127 @default.
• W4387362004 creator A5032153581 @default.
• W4387362004 creator A5042445499 @default.
• W4387362004 creator A5047924629 @default.
• W4387362004 creator A5048208357 @default.
• W4387362004 creator A5049604838 @default.
• W4387362004 creator A5059954033 @default.
• W4387362004 creator A5069954158 @default.
• W4387362004 creator A5087343135 @default.
• W4387362004 creator A5088220553 @default.
• W4387362004 date "2023-10-01" @default.
• W4387362004 modified "2023-10-06" @default.
• W4387362004 title "THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand" @default.
• W4387362004 doi "https://doi.org/10.1210/jendso/bvad114.1130" @default.
• W4387362004 hasPublicationYear "2023" @default.
• W4387362004 type Work @default.
• W4387362004 citedByCount "0" @default.
• W4387362004 crossrefType "journal-article" @default.
• W4387362004 hasAuthorship W4387362004A5011213787 @default.
• W4387362004 hasAuthorship W4387362004A5028154666 @default.
• W4387362004 hasAuthorship W4387362004A5029381127 @default.
• W4387362004 hasAuthorship W4387362004A5032153581 @default.
• W4387362004 hasAuthorship W4387362004A5042445499 @default.
• W4387362004 hasAuthorship W4387362004A5047924629 @default.
• W4387362004 hasAuthorship W4387362004A5048208357 @default.
• W4387362004 hasAuthorship W4387362004A5049604838 @default.
• W4387362004 hasAuthorship W4387362004A5059954033 @default.
• W4387362004 hasAuthorship W4387362004A5069954158 @default.
• W4387362004 hasAuthorship W4387362004A5087343135 @default.
• W4387362004 hasAuthorship W4387362004A5088220553 @default.
• W4387362004 hasBestOaLocation W43873620041 @default.
• W4387362004 hasConcept C104317684 @default.
• W4387362004 hasConcept C113675107 @default.
• W4387362004 hasConcept C126322002 @default.
• W4387362004 hasConcept C134018914 @default.
• W4387362004 hasConcept C2776297358 @default.
• W4387362004 hasConcept C2777433750 @default.
• W4387362004 hasConcept C2778886798 @default.
• W4387362004 hasConcept C2779371878 @default.
• W4387362004 hasConcept C2781025020 @default.
• W4387362004 hasConcept C2984496839 @default.
• W4387362004 hasConcept C36823959 @default.
• W4387362004 hasConcept C54355233 @default.
• W4387362004 hasConcept C71315377 @default.
• W4387362004 hasConcept C71924100 @default.
• W4387362004 hasConcept C86803240 @default.
• W4387362004 hasConceptScore W4387362004C104317684 @default.
• W4387362004 hasConceptScore W4387362004C113675107 @default.
• W4387362004 hasConceptScore W4387362004C126322002 @default.
• W4387362004 hasConceptScore W4387362004C134018914 @default.
• W4387362004 hasConceptScore W4387362004C2776297358 @default.
• W4387362004 hasConceptScore W4387362004C2777433750 @default.
• W4387362004 hasConceptScore W4387362004C2778886798 @default.
• W4387362004 hasConceptScore W4387362004C2779371878 @default.
• W4387362004 hasConceptScore W4387362004C2781025020 @default.
• W4387362004 hasConceptScore W4387362004C2984496839 @default.
• W4387362004 hasConceptScore W4387362004C36823959 @default.
• W4387362004 hasConceptScore W4387362004C54355233 @default.
• W4387362004 hasConceptScore W4387362004C71315377 @default.
• W4387362004 hasConceptScore W4387362004C71924100 @default.
• W4387362004 hasConceptScore W4387362004C86803240 @default.
• W4387362004 hasIssue "Supplement_1" @default.
• W4387362004 hasLocation W43873620041 @default.
• W4387362004 hasOpenAccess W4387362004 @default.
• W4387362004 hasPrimaryLocation W43873620041 @default.
• W4387362004 hasRelatedWork W2005703684 @default.
• W4387362004 hasRelatedWork W2008013589 @default.
• W4387362004 hasRelatedWork W2471639376 @default.
• W4387362004 hasRelatedWork W2612643283 @default.
• W4387362004 hasRelatedWork W2886271964 @default.
• W4387362004 hasRelatedWork W3037156209 @default.
• W4387362004 hasRelatedWork W3134187993 @default.
• W4387362004 hasRelatedWork W4211191881 @default.
• W4387362004 hasRelatedWork W4301494825 @default.
• W4387362004 hasRelatedWork W73203029 @default.
• W4387362004 hasVolume "7" @default.
• W4387362004 isParatext "false" @default.
• W4387362004 isRetracted "false" @default.
• W4387362004 workType "article" @default.